title: Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.
abstract: BACKGROUND
  Because of the increasing number of long-term survivors of metastatic testicular germ-cell cancer, a general concern has been secondary morbidities, especially cardiovascular risk factors.
  
  
  METHODS
  Thirty-two patients treated with cisplatin- and doxorubicin-containing chemotherapy > or = 13 years before the time of analyses were evaluated for neuro-, oto-, pulmonary-, vascular- and gonadal toxicity including evaluation of myocardial damage and cardiovascular risk factors and analysis of microcirculation.
  
  
  RESULTS
  Thirty percent of the patients showed abnormal left ventricle function. Elevated follicle stimulating hormone (FSH) and luteinising hormone (LH) levels in 75% of patients were often associated with low testosterone levels. Elevated total cholesterol levels were found in 82% and higher triglyceride levels in 44% of patients, most of them were overweight. About 25% of the patients developed diastolic arterial hypertension after chemotherapy. Reduced hearing was confirmed in 23% of patients, especially at frequencies higher than 3000 Hz. Moreover, 53% of patients presented transient evoked otoacoustic emissions. In 38% of patients non-symptomatic neuropathy was detected, in 28% symptomatic neuropathy, and in 6% disabling polyneuropathy. In 80% of patients with neuropathic symptoms additional morphological and functional abnormalities were found by nailfold capillary videomicroscopy, compared to only 57% of the patients without neuropathic symptoms.
  
  
  CONCLUSIONS
  Patients cured by cisplatin-based chemotherapy for metastatic testicular cancer have to be cognizant of their unfavorable cardiovascular risk profile, that might be a greater risk than developing a relapse or second malignancy.
authors.affiliation: Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen. dirk.strumberg@uni-essen.de
authors.forename: D
authors.initials: D
authors.lastname: Strumberg
authors.forename: S
authors.initials: S
authors.lastname: Brügge
authors.forename: M W
authors.initials: MW
authors.lastname: Korn
authors.forename: S
authors.initials: S
authors.lastname: Koeppen
authors.forename: J
authors.initials: J
authors.lastname: Ranft
authors.forename: G
authors.initials: G
authors.lastname: Scheiber
authors.forename: C
authors.initials: C
authors.lastname: Reiners
authors.forename: C
authors.initials: C
authors.lastname: Möckel
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: M E
authors.initials: ME
authors.lastname: Scheulen
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D002945:Cisplatin / Q000009:adverse effects*; D005298:Fertility / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D006309:Hearing / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D013736:Testicular Neoplasms / Q000188:drug therapy*
chemical_list: D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002945:Cisplatin